Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of GMED's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Sep 19, 2024
Questions asked 59 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 59 numbered comments
  3. 3. Company replies 7 CORRESP
  4. 4. Reviews closed 3 of 4 closing letter

Half the closed reviews took 19 days or less from the first letter to the closing letter.

Form 10-K

2024-09-19 to 2024-10-04 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2024-10-04
Non-GAAP measuresAcquisitionsResults discussion (MD&A)
Exhibit 99.1, page 3
SEC asked (2)
We note your non-GAAP measures include an adjustment for an in-process research and development (IPR&D) charge incurred in connection with your asset acquisition. We believe the adjustment for IPR&D is inconsistent with Question 100.01 of the CD&I on Non-GAAP Financial Measures.
Rest of the question

Please confirm to us you will no longer include the adjustment in any non-GAAP financial measure presented in accordance with Item 10(e) of Regulation S-K or Regulation G.

GMED answered
The Company acknowledges the Staff's comment and respectfully advises the Staff that beginning with the disclosure for the Form 8-K, Exhibit 99.1 for the results of the quarter ended September 30, 2024, the Company will no longer include the adjustment for in-process research and development in any non-GAAP financial measure presented in accordance with Item 10(e) of Regulation S-K or Regulation G.
Read in the reply
In its next report

First report after the company's reply of Oct 2, 2024: 10-Q filed Nov 5, 2024 ↗, against the 10-Q filed Aug 6, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 3
SEC asked (3)
In future filings, please quantify the components within acquisition related costs/licensing. In addition, describe the nature of the licensing fee included and explain to us how this adjustment meets the requirements of Question 100.01 of the C&DI on Non-GAAP Financial Measures.
GMED answered
The Company acknowledges the Staff's comment and respectfully advises the Staff that beginning with the disclosure for the Form 8-K, Exhibit 99.1 for the results of the quarter ended September 30, 2024, the Company will include in tabular format the quantification of the components of acquisition related costs within our Form 8-K filings. In addition, we will change the line name from “Merger and acquisition-related costs/licensing” to “Merger and acquisition-related costs”.
Rest of the answer

The licensing costs represented one-time contract break fees associated with merger and acquisition activity, and therefore, are not normal, recurring, operating expenses for the Company. Given the immaterial value of these fees, we believe that including these costs in the “Other acquisition-related costs” line and that removing reference to “licensing” from the category will be more descriptive of the material components. The Company has included a sample in Table 1 below.

Table 1:

Three Months Ended

Nine Months Ended

September 30,

(In thousands)

2024

2023

Amortization of inventory fair value step up

$

Change in fair value of business acquisition liabilities

Employee-related costs

Other acquisition-related costs (a)

Merger and acquisition-related costs

(a) Primarily comprised of legal fees, investment banking and consulting fees.

The Company intends the above table will be a stand-alone table and everywhere we refer to “Merger and acquisition-related costs” we will include a footnote and refer the reader to this table.

Read in the reply
In its next report

First report after the company's reply of Oct 2, 2024: 10-Q filed Nov 5, 2024 ↗, against the 10-Q filed Aug 6, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 3
SEC asked (4)
In future filings, please reconcile adjusted gross profit to the most directly comparable GAAP measure, as required by Item 10(e)(1)(i)(B) of Regulation S-K, and present gross profit as a percentage of net sales with more prominence than adjusted gross profit as a percentage of net sales in accordance with Item 10(e)(1)(i)(A) of Regulation S-K.
GMED answered
The Company acknowledges the guidance in Item 10(e)(1)(i)(A) and Item 10(e)(1)(i)(B) of Regulation S-K. The Company respectfully advises the Staff that beginning with disclosure for the quarter ending September 30, 2024, the Company will reconcile gross profit and gross profit as a percentage of net sales to adjusted gross profit and adjusted gross profit as a percentage of net sales and present gross profit as a percentage of net sales with more prominence than adjusted gross profit as a percentage of net sales. The Company has included a sample in Table 2 below.

Table 2:
Read in the reply
In its next report

First report after the company's reply of Oct 2, 2024: 10-Q filed Nov 5, 2024 ↗, against the 10-Q filed Aug 6, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 3
SEC asked (5)
As a related matter, we note that you are presenting amortization of intangible separately and presenting a gross profit measure. Please tell us your consideration of the guidance in SAB Topic 11:B and how you concluded that the gross profit measure is fully burdened.
Rest of the question

In addition, if the gross profit presented on the face of the income statement is not materially fully burdened, it will need to be in order to present adjusted gross profit for purposes of complying with Item 10(e)(1)(i)(A) and (B) of S-K.

GMED answered
The Company acknowledges the guidance in SAB Topic 11:B and has availed itself in accordance with the topic to the presentation option of separately disclosing its amortization of intangibles on a separate financial statement line. The Company’s amortization of intangible assets includes amortization of supplier networks, customer relationships & other intangibles, developed technology, and patents. Due to the nature of these intangible assets, the Company utilizes them across a variety of our products and throughout a variety of functional departments.
Rest of the answer

As such, we believe presenting the amortization of intangibles separately aligns best with our operations.

The Company, beginning with the disclosure for the Form 10-Q and Form 8-K, Exhibit 99.1 for the results of the quarter ended September 30, 2024, will remove the gross profit measure from the face of our Statement of Operations and Comprehensive Income and add the parenthetical notation “(exclusive of amortization of intangibles)” to the title for cost of sales. The Company has included a sample in Table 3 below.

Table 3:

Cost of Sales and Operating expenses:

Cost of sales (exclusive of amortization of intangibles)

Research and development

Selling, general and administrative

Provision for litigation, net

Amortization of intangibles

Acquisition-related costs

Restructuring Costs

Operating income/(loss)

Other income/(expense), net:

Interest income/(expense), net

Foreign currency transaction gain/(loss)

Other income/(expense)

Total other income/(expense), net

Income/(loss) before income taxes

Income tax provision/(benefit)

Net income/(loss)

Other comprehensive income/(loss), net of tax:

Unrealized gain/(loss) on marketable securities

Foreign currency translation gain/(loss)

Total other comprehensive income/(loss), net of tax

Comprehensive income/(loss)

Earnings per share:

Basic

Diluted

Weighted average shares outstanding:

Separately, we will include a supplementary table in our Form 8-K filings beginning with disclosure for the quarter ending September 30, 2024. The Company will disclose gross profit, fully burdened by amortization of intangible assets that facilitate revenue producing activities, along with a reconciliation to adjusted gross profit. The Company refers you to our response to Staff comment #4, Table 2, as an example of our supplemental Form 8-K disclosure.

***

We understand that the Company and its management are responsible for the accuracy and adequacy of our disclosures, notwithstanding any review, comments, action or absence of action by the Staff.

If you require any additional information on these issues, or if we can provide you with any other information that will facilitate your review, please contact me at 610-930-1800 ext. 1915.

Read in the reply
In its next report

First report after the company's reply of Oct 2, 2024: 10-Q filed Nov 5, 2024 ↗, against the 10-Q filed Aug 6, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-10-04

Form 10-K

2016-07-15 to 2016-08-11 · 8 questions · 1 letter from the SEC, 1 from the company
Review closed 2016-08-11
Non-GAAP measuresResults discussion (MD&A)AcquisitionsLegal and contingenciesRevenue
Item 7. Management’s Discussion of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 61
SEC asked (1)
We note that your non-GAAP measures, adjusted EBITDA and non-GAAP diluted earnings per share, exclude certain normal, recurring, operating items such as your provision (recoveries) for litigation and costs arising from acquisitions, which may be inconsistent with the updated Compliance and Disclosure Interpretations issued on May 17, 2016.
Rest of the question

Please review that guidance when preparing your future filings and earnings releases.

GMED answered
We have reviewed the Compliance and Disclosure Interpretations issued on May 17, 2016 (the “New C&DIs”) and will evaluate our disclosures accordingly when preparing future filings and earnings releases. We believe that adjusted EBITDA and non-GAAP diluted earnings per share calculations are consistent with the New C&DIs and are valuable disclosures as they make it easier for investors to compare financial performance in periods that contain large and unusual items such as litigation settlements and cost arising from acquisitions that can vary significantly in the periods presented.
Rest of the answer

We do evaluate which fees are normal, recurring operating expenses and do not include those in the adjustment. For example, the provision

Mr. Brian Cascio

United States Securities and Exchange Commission

(recoveries) for litigation generally only includes probable or actual litigation settlements, verdicts, etc. In future filings, we will provide examples of expenses that are components of the adjustments such as the following 6/30/16 10-Q disclosure:

“Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related items represents the change in fair value of business acquisition related contingent consideration; costs related to integrating recently acquired businesses including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees."

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management’s Discussion of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 61
SEC asked (2)
You present adjusted EBITDA as a percentage of sales without also presenting the comparable GAAP measure. It appears that your presentation gives more prominence to the non-GAAP measure which is inconsistent with the updated Compliance and Disclosure Interpretations issued on May 17, 2016. Please review that guidance when preparing your future filings and earnings releases.
GMED answered
In future filings, we will add Net Income as a percentage of sales to our disclosure to ensure that adjusted EBITDA is not given more prominence than Net Income, a GAAP financial measure. Below is our 6/30/16 10-Q disclosure:

The following is a reconciliation of net income to Adjusted EBITDA for the periods presented:

Three Months Ended

Six Months Ended

(In thousands, except percentages)

June 30,

2016

2015

Net Income

$

25,806

24,054

53,816

48,702

Interest income, net

(602

)

(278

(1,098

(556

Provision for income taxes

12,530

13,417

28,131

26,942

Depreciation and
Rest of the answer

amortization

7,022

5,905

13,698

11,579

EBITDA

44,756

43,098

94,547

86,667

Stock-based compensation expense

2,920

2,538

5,690

4,669

Provision for litigation

3,056

374

406

Acquisition related items

(519

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management’s Discussion of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 61
SEC asked (3)
We note that in reconciling non-GAAP diluted earnings per share to the comparable GAAP measure you present the adjustments net of tax, which is inconsistent with Question 102.11 of the updated Compliance and Disclosure Interpretations issued on May 17, 2016. Please review that guidance when preparing your future filings and earnings releases.
GMED answered
In future filings and earnings releases, we will present the adjustments on a gross basis and show income taxes as a separate adjustment with a clear explanation. Below is our 6/30/16 10-Q disclosure:

“In addition, for the period ended June 30, 2016 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represents net income and diluted earnings per share excluding the provision for litigation, acquisition related items, and adjusted for the tax effects of such adjustments.
Rest of the answer

We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, acquisition related items, and adjusted for tax affects of such adjustments, which we believe is not reflective of underlying business trends.”

“The following is a reconciliation of net income computed in accordance with U.S. GAAP to non-GAAP net income for the periods presented.”

(In thousands)

Net income

Tax effect of adjusting items

(847

(398

(1,072

(614

Non-GAAP net income

27,496

24,760

55,955

49,808

“The following is a reconciliation of Diluted Earnings Per Share as computed in accordance with U.S. GAAP to non-GAAP Diluted Earnings Per Share for the periods presented.”

(Per share amounts)

Diluted earnings per share, as reported

0.27

0.25

0.56

0.51

0.03

—

(0.01

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management’s Discussion of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 61
SEC asked (4)
On page 63 you disclose the percentage change in Revenues and in Net Income measured in constant currencies. Although you also present the GAAP amount and GAAP calculated percentage change, since you do not also present the constant currency amount an investor is not able to determine how the constant currency percentage change is calculated.
Rest of the question

Please revise your presentation in future filings to provide quantified reconciliations to the comparable change measured according to GAAP or to clearly show the calculations of the constant currency percentage change. Refer to Item 10(e)(1)(i)(B) of Regulation S-K and Question 104.06 of the Compliance and Disclosure Interpretations.

GMED answered
In future filings, we will add the constant currency amount and revise the description of the constant currency calculation to clearly describe how we determine the exchange rates used in measuring constant currency amounts, including the period of the rates being used, to make the presentation clearer to the investor. Below is our 6/30/16 10-Q disclosure:

“Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period.
Rest of the answer

We believe constant currency sales growth provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Below is a reconciliation of sales growth as reported in accordance with U.S. GAAP compared to constant currency sales growth for the periods presented.”

Reported Sales Growth

Currency Impact on Current Period Sales

Constant Currency Sales Growth

United States

124,716

121,487

2.7

International

12,773

12,083

5.7

(287

8.1

Total sales

137,489

133,570

2.9

3.1

252,276

241,470

4.5

24,477

23,704

3.3

(823

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management’s Discussion of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 61
SEC asked (5)
Your disclosure on page 63 that you define the non-GAAP measures of sales and net income on a constant currency basis as the current and prior period sales and net income translated at the “same predetermined exchange rate” is unclear.
Rest of the question

Please revise your presentation in future filings to clearly describe how you determine the exchange rates used in measuring constant currency amounts, including the dates or period of the rates being used.

GMED answered
In future filings, we will revise the description of the constant currency calculation to clearly describe how we determine the exchange rates used in measuring constant currency amounts, including the period of the rates being used, to make the presentation clearer to the investor. The following is our 6/30/16 10-Q disclosure:

“Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period.”
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 8. Financial Statements · Note 2. Acquisitions, page 86
SEC asked (6)
With respect to the BMG acquisition, in future filings please describe the nature of the deferred consideration, the terms and manner of settlement and the accounting applied. Refer to ASC 805-30 and ASC 850-10-50.
GMED answered
With respect to the BMG acquisition, in future filings, we will describe the nature of the deferred consideration, the terms and manner of settlement and the accounting applied. The following is our 6/30/16 10-Q disclosure:

“On February 25, 2015, we entered into an agreement to acquire Branch Medical Group, Inc. (“BMG”), a related-party manufacturer of high precision medical devices located in Audubon, PA. We closed this acquisition on March 11, 2015, for $57.0 million in cash, $5.3 million in deferred consideration, and $0.9 million of closing working capital adjustments.
Rest of the answer

The amount payable to BMG on the date of acquisition of $5.2 million was also settled in connection with the acquisition. The deferred consideration was a holdback of a portion of the sale price, to allow time to properly account for all working capital adjustments in the event of an unfavorable adjustment to the sellers. The full holdback amount of $5.3 million was paid in cash in July 2016.”

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 3. Intangible Assets, page 91
SEC asked (7)
We see that the carrying amount of In-process Research and Development is unchanged from the date of the most recent addition which occurred during the year ended December 31, 2013. Please describe to us the principal components of the asset, the status of the underlying projects and the factors you have considered in concluding that the carrying amount continues to be recoverable.
GMED answered
The principal components of the IPR&D are $20.5M for the Excelsius acquisition in December 2013 and $4.1M for the Facet acquisition in January 2011. These projects are still under development and not commercialized and will remain indefinite-lived assets until the completion (or abandonment) of the associated research and development efforts which are expected to be in 2016 for the Excelsius robot following an FDA submission and in 2020-2021 for Facet following an in-process clinical trial and/or another planned clinical trial utilizing a combination of two products.
Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 5. Fair Value Measurements, page 93
SEC asked (8)
In future filings please disclose the specific valuation techniques and inputs used in measuring the fair values of the investment securities classified as Level 2 in your disclosure. Refer to ASC 820-10-50-2bbb.
GMED answered
In future filings, we will disclose the specific valuation techniques and inputs used in measuring the fair values of the investment securities classified as Level 2. Below is our 6/30/16 10-Q disclosure:

“Our marketable securities are classified as Level 2 within the fair value hierarchy, as we measure their fair value using market prices for similar instruments and inputs such as actual trade data, benchmark yields, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors.”

In addition, Globus understands and hereby acknowledges
Rest of the answer

that:

•

We are responsible for the adequacy and accuracy of the disclosures in our SEC filings;

Staff comments or changes to disclosures in response to staff comments do not foreclose the Commission from taking any action with respect to our SEC filings; and

We may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Jul 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed May 4, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2016-08-11

Form 10-K for the fiscal year ended December 31, 2012

2013-05-30 to 2013-06-18 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2013-06-18
Related-Party Transactions, page 86
SEC asked (1)
Your related party transactions disclosure should provide all of the disclosures required by Regulation S-K Item 404(a). Please include such disclosure in your future filings – including any amendment – as appropriate. For example, you should specifically name the officer or director who is a related person and that related person’s ownership in the other entity.
Rest of the question

We note that this disclosure was included in your registration statement on Form S-1 in connection with your initial public offering.

GMED answered
In response to your comment, we are filing, concurrently with this response letter, an amendment to our Form 10-K in which we have revised the language under the heading “Related-Party Transactions” on page 87 of the Form 10-K/A and included in Item 13 on page 126 of the Form 10-K/A related party transactions disclosure consistent with that found in our registration statement on Form S-1.
Rest of the answer

We confirm that, in future filings, to the extent applicable, our related party transactions disclosure will be consistent with that found in our registration statement on Form S-1 and the requirements of Regulation S-K Item 404(a).

Read in the reply
In its next report

First report after the company's reply of Jun 13, 2013: 10-Q filed Aug 2, 2013 ↗, against the 10-Q filed May 3, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Signatures
SEC asked (2)
Please file a complete amendment to your Form 10-K with a Signatures page that includes all language that Form 10-K requires on a Signatures page, includes all required signatures on that Signatures page, and identifies who is signing in the capacity of principal accounting officer or controller.
GMED answered
As noted in response to comment 1, we are filing, concurrently with this response letter, a complete amendment to our Form 10-K with a Signatures page that includes all language that Form 10-K requires on a Signatures page, includes all required signatures on that Signatures page, and identifies who is signing in the capacity of principal accounting officer or controller.

As requested in your comment letter dated May 30, 2013, the Company acknowledges that:

• the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

staff comments or changes to disclosure in
Rest of the answer

response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: closing letter, 2013-06-18

Form S-1

2012-04-25 to 2012-07-03 · 45 questions · 2 letters from the SEC, 4 from the company
No closing letter
Results discussion (MD&A)Critical estimatesRisk factorsLiquidity and cashRevenueInventoryReserves and insuranceNon-GAAP measuresLegal and contingenciesChina
General
SEC asked (1)
Since you appear to qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (“the Act”), please disclose on your prospectus cover page that you are an emerging growth company, and revise your prospectus to provide the following additional disclosures:  Describe how and when a company may lose emerging growth company status;  A brief description of the various
Rest of the question

exemptions that are available to you, such as exemptions from Section 404(b) of the Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the Securities Exchange Act of 1934; and  Your election under Section 107(b) of the Act: o If you have elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act, include a statement that the election is irrevocable; or o If you have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2)(B) of the Act, provide a risk factor explaining that this election allows you to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Please state in your risk factor that, as a result of this election, your financial statements may not be comparable to companies that comply with public company effective dates. Include a similar statement in your critical accounting policy disclosures in MD&A.

GMED answered
The Company is an “emerging growth company” within the meaning of the Act. The Company has revised the disclosure on its prospectus cover page to indicate it is an emerging growth company, and it has also revised the disclosure on page 5 to describe the exemptions available to the Company as an emerging growth company.
Rest of the answer

Furthermore, the Company has revised the risk factor disclosure on pages 45 through 47, the critical accounting policy disclosures on page 73 and the recent issued accounting pronouncements disclosure on pages 80 and 81 to disclose the exemptions available to the Company under the Act and its election to use the extended transition period for complying with new or revised accounting standards.

Read in the reply
Prospectus Summary, page 1
SEC asked (2)
Please add disclosure that briefly explains more clearly the breakdown between and changes in your sources of revenue attributable to fusion and disruptive products, your present heavy reliance on 2 specific product lines identified on page 83 and the fact that your recent growth is primarily attributable to the introduction of new products.
GMED answered
In response to the

Staff’s comment, the Company has revised its disclosure on pages 1 and 2 to explain the breakdown between, and changes to, its sources of revenue attributable to its innovative fusion and disruptive technology products. The Company has also revised its disclosure on page 2 to explain the fact that its recent growth is primarily attributable to the introduction of new products.

The Company has also revised its risk factor disclosure on page 13 to demonstrate its reliance on three specific products.
Rest of the answer

Further, the Company advises the Staff that it has referenced the importance of its sales from the aforementioned products in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 66, 67 and 69 as well as disclosed its reliance on these three products in “Business – Products” on page 89. The Company has not included additional disclosure in the prospectus summary and respectfully advises the Staff that it has provided extensive disclosure on this topic and believes that further disclosure in the summary would be duplicative and not helpful to an investor.

Read in the reply
Our Business, page 1
SEC asked (3)
Please revise to remove individual results from prior periods or provide sufficiently detailed information so that an investor is able to fully evaluate the prior period results to the same extent they can evaluate results where you provide full financial statement disclosure.
Rest of the question

In addition, please avoid the use of compound annual growth rate as it provides limited information about significant short term changes in values measured.

GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 1, 82, and 88 to delete references to sales for 2004 and instead to present sales revenue growth from the

Company’s inception to 2011 to better permit an investor to evaluate the sales growth experienced by the Company since it was formed. Additionally, the Company has deleted references to “compound annual growth rate.”
Read in the reply
Our Business, page 1
SEC asked (4)
Please provide us with objective, independent support for the statements regarding your “unique and highly efficient” product development throughout. In this regard, tell us how you believe your process differs from that of your competitors.
GMED answered
In response to the Staff’s comment, the Company has revised references to its product development engine to clarify that it believes its product development engine is unique and highly efficient.

The Company advises the Staff that it believes that its product development engine differs from those of its competitors primarily in the nature in which it is operated.
Rest of the answer

The Company uses cross-functional teams that enable its engineers to gather input from surgeons, who provide valuable insight with respect to issues of importance to the

Company’s customers, the Company’s dedicated researchers, who perform non-clinical research that provides additional insight to biomechanical and other matters, the Company’s machinists, who provide guidance and input with respect to manufacturing issues and means of addressing those issues, and the Company’s clinical and regulatory personnel, who provide input on design matters that might affect the Company’s ability to obtain clearance or approval to market a device and/or the claims that the Company can make in marketing that device. The Company also possesses testing and other laboratories, as well as its own in-house prototyping shop, that enable it to design, test and refine products very quickly. The reason for using the Company’s integrated team approach and in-house facilities is to develop and launch better products faster than its competition. The Company’s management team has a deep and diverse background in the spine industry and is not aware of any competitor that approaches product development in this manner.

Read in the reply
Our Business, page 1
SEC asked (5)
Throughout your disclosure where you cite industry statistics, please provide us copies of source materials marked to indicate the origin of the disclosure.
GMED answered
In response to the Staff’s comment, the Company is providing to the Staff, under separate cover, a supplemental binder containing marked copies of source materials cited in various places in the Registration Statement.
Read in the reply
The Offering, page 5
SEC asked (6)
Please provide summary disclosure regarding the effects of the reverse stock split referenced on page i, including the stock split ratios, whether the split would apply to both classes of common stock equally, and the impact on your authorized share capital.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 8 of the Registration Statement to enhance its disclosure to describe the effects of the reverse stock split, including the possible stock split ratios, the classes of stock subject to the stock split and the impact on the Company’s authorized share capital. The Company advises the Staff that when the stock split ratio has been determined, it will revise its disclosure to reflect the effectuation of the reverse stock split.
Read in the reply
Summary Consolidated Financial Data, page 8
SEC asked (7)
We note that the pro forma basic and diluted net income per share data assumes the automatic conversion of all shares of your Series E preferred stock into shares of your Class B common stock and the automatic conversion of all shares of your Class C common stock into shares of your Class A common stock. Please tell us why the pro forma adjusted balance sheet does not include adjustments for these events.
GMED answered
The Company respectfully advises the Staff that the pro forma as adjusted balance sheet, when the share numbers are determined and such balance sheet is presented in complete form, will reflect all adjustments included in the pro forma balance sheet and thus include the adjustment for the automatic conversion of all shares of Series E preferred stock into shares of Class B common stock, the automatic conversion of all shares of Class B common stock held by those who own less than 10% of the aggregate number of all outstanding shares of the Company’s common stock, and the automatic conversion
Rest of the answer

of all shares of Class C common stock into shares of Class A common stock, and will also be further adjusted to reflect the automatic conversion of shares of Class B common stock to shares of Class A common stock upon their sale by the selling stockholders in the offering and to reflect the issuance by the Company of shares of Class A common stock in the offering. In response to the Staff’s comment, the Company has revised the disclosure in notes (3) and (5) to Summary Consolidated Financial Data on pages 10 and

12 to clarify that the pro forma balance sheet data reflects such conversions and that the pro forma as adjusted balance sheet data reflects the pro forma balance sheet data, and thus all of the conversions reflected therein, as adjusted to reflect the issuance and sale of shares of Class A common stock in the initial public offering.

Read in the reply
Summary Consolidated Financial Data, page 8
SEC asked (8)
We note the unaudited pro forma net income for the year ended December 31, 2011 of $61.1 million. We also see the reference to footnote (3). Please disclose the nature and amount of adjustments to derive the pro forma net income. Please similarly revise your Selected Consolidated Financial Data on page 57. Discuss your consideration of Rule 11-02(b)(6) of Regulation S-X.
GMED answered
In response to the

Staff’s comment, the Company has revised its disclosure in footnote (3) to the Summary Consolidated Financial Data on page 10 and in footnote (3) to the Selected Consolidated Financial Data on pages 60 and 61 to include the nature and the amount of the adjustments to derive the pro forma net income. The Company considered Rule 11-02(b)(6) of Regulation S-X and believes the criteria indicated therein have been met because, upon the terms of the Put Right agreement, the Put Right will be cancelled upon the closing of the initial public offering.
Read in the reply
Risk Factors, page 12 · Pricing pressure from our competitors, page 13
SEC asked (9)
Please revise to clarify the extent to which your products are currently covered by thirdparty payors. Disclose when the referenced coverage policy changes occurred and quantify the impact and potential impact on you of these or any other pending or recent coverage changes.
GMED answered
The Company respectfully advises the Staff that it cannot confirm the extent to which its products and procedures using its products are currently covered by third-party payors, because the Company does not bill any third-party payor. The Company’s customers, which are typically facilities such as hospitals and surgery centers where its products are used, bill third-party payors to cover all or a portion of the costs and fees associated with the procedures in which the Company’s products are used, including the cost to purchase the Company’s products.
Rest of the answer

Because the Company’s customers rely on such third-party reimbursement, changes in the amount that payors are willing to reimburse the Company’s customers for procedures using the Company’s products could create pricing pressure for the Company, and its business could be negatively impacted if such payors reduce or eliminate coverage of and/or reimbursement for procedures using its products. In response to the Staff’s comment, however, the Company has revised the disclosure on page 14 to further clarify that its customers, rather than the Company directly, rely on third-party reimbursement.

The Company has further revised the disclosure on page 14 to identify when the referenced coverage policy changes occurred. The Company has not experienced a material adverse impact on its business due to these coverage policy changes, but its business would be negatively impacted if the trend by third-party payors continues to reduce coverage of and/or reimbursement for procedures using its products. In response to the Staff’s comment, however, the Company has revised page 14 to enhance the disclosure of the potential negative impact of the coverage decisions.

Read in the reply
We are dependent, page 16
SEC asked (10)
We note your disclosure regarding reliance on a limited number of suppliers. Please file all agreements that are material contracts required to be filed by Item 601 of Regulation S-K. Refer to Item 601(b)(10)(ii)(B).
GMED answered
The Company respectfully advises the Staff that none of its agreements with suppliers are material contracts required to be filed by Item 601 of

Regulation S-K. In response to the Staff’s comment, the Company has revised the disclosure on page 17 to indicate that the agreements between the Company and its suppliers set forth terms, such as quality and delivery requirements, by which the

Company would purchase products from the supplier if the supplier were to accept a purchase order from the Company, but do not obligate the Company to purchase a particular quantity of products from any
Rest of the answer

supplier and do not obligate any supplier to supply a particular quantity of products to the Company.

Read in the reply
If we do not enhance our product offerings, page 19
SEC asked (11)
Please expand this or another risk factor to clarify the extent to which you rely upon two lines of products as disclosed in the first paragraph on page 83.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 13 to clarify the extent to which it relies on three products as disclosed in the first paragraph under “Products” on page 89.
Read in the reply
Our medical device products, page 23
SEC asked (12)
We note the last paragraph of this risk factor on page 26, and your February 29, 2012 press release. With a view towards additional risk factor disclosure, please tell us whether you continued to sell your product without 510(k) clearance after the Food and Drug Administration determined that 510(k) clearance was required.
Rest of the question

If so, please tell us the extent to which these sales could impact your product liability risk, and explain how such sales were consistent with the first sentence of the last risk factor on page 18.

GMED answered
The Company advises the

Staff that it commenced selling its NuBone product in 2007 in reliance upon the minimally manipulated tissue exemption to the 510(k) pre-market notification requirements of the Food, Drug and Cosmetic Act. In March 2008, the Food and Drug

Administration notified the Company of its determination that NuBone did not meet all of the criteria of minimally manipulated tissue and that NuBone was thus regulated as a device.
Rest of the answer

The Company agreed to submit a 510(k) pre-market submission within one year, following completion of the required testing, and in fact submitted the 510(k) in December 2008. During the period of time, the Company continued to sell NuBone, was in regular communication with the FDA, and believed, based on these communications, that its continued sale of the NuBone product was acceptable to the FDA. In December 2009, the Company received correspondence from the FDA expressing the FDA’s determination that NuBone was not substantially equivalent to any legally marketed device. Sales of NuBone in the United States continued until December 2010. The civil complaint that the Company settled with the FDA in February 2012 alleged that the sale of 67 units that occurred between the date of the

FDA’s “not substantially equivalent” letter in December 2009 and September 2010 occurred without the requisite 510(k) clearance. Under the terms of the settlement agreement with the FDA, the FDA has released the Company from all claims by the FDA with respect to sales of NuBone, without admission of liability or fault by the Company.

Over 11,700 units of NuBone were sold by the Company prior to December 2010, and the Company has not been made aware of any material safety issues or other adverse events due to NuBone. As a result, the Company does not believe that the sales of NuBone between December 2009 and September 2010 could impact the Company’s product liability risk.

The Company further advises the Staff that the first sentence of the last risk factor on page 19 (“The safety and efficacy of our products”) specifically states that “[t]he products [the Company] currently market[s] in the United States have either received pre-market clearance under Section 510(k) of the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, or are exempt from pre-market review.” NuBone is not a product that the Company “currently markets” in the United States, and historical sales of NuBone therefore do not contradict that sentence.

Read in the reply
Capitalization, page 52
SEC asked (13)
Please remove the line, cash and cash equivalents, from your capitalization table.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 54 to remove the line, cash and cash equivalents, from the capitalization table.
Read in the reply
Capitalization, page 52
SEC asked (14)
We reference the discussion in the second paragraph following the table. Please tell us whether you intend to revise the actual pro forma adjustment shown in the table, and in other disclosures where you provide a similar pro forma adjustment to reflect the automatic conversion of the Series E preferred stock, to reflect the conversion rate based upon the midpoint of the price range of the offering.
Rest of the question

If not, please explain why.

GMED answered
The Company respectfully advises the Staff that all outstanding shares of Series E preferred stock will automatically convert to shares of our Class B common stock on a one-to-one basis unless the initial public offering price falls below a specified minimum dollar amount, in which case the conversion rate would increase. The pro forma adjustment to reflect the automatic conversion of the Series E preferred stock currently included in the prospectus assumes the initial public offering price exceeds such minimum dollar amount.
Rest of the answer

The Company hereby confirms its intent to revise the actual pro forma adjustment shown in the capitalization table, and in other disclosure where it provides a similar pro forma adjustment, to reflect the automatic conversion of the Series E preferred stock to reflect the conversion rate based upon the midpoint of the price range of the offering when the price range is included in the prospectus if the minimum dollar amount that would trigger a change in the conversion rate falls within the estimated price range of the offering.

Read in the reply
Dilution, page 55
SEC asked (15)
Please tell us why you have not quantified the dilution that would result assuming the exercise of all outstanding stock options or revise.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure to quantify the dilution that would result assuming the exercise of all outstanding stock options.

The following sentence is included in the third full paragraph on page 58:

“To the extent that outstanding options are exercised, you will experience further dilution.
Rest of the answer

If all of our outstanding options were exercised, our net tangible book value as of March 31, 2012 would have been $ or $ , per share, and the net tangible book value after this offering would have been $ , or $ per share, causing dilution to new investors of $ per share.”

Read in the reply
Management’s Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 63
SEC asked (16)
We note the increase in cost of goods sold in 2011 was due in part to an increase in inventory reserves and scrap of $5.7 million. Please disclose the significant causes of the increase. Please reconcile the amount with your disclosure on page F-7 regarding the provision for excess and obsolete inventories. Refer to Item 303(A)(3) of Regulation S-K and the related instructions.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure under “Cost of Goods Sold” on page 68 to indicate that the significant cause of the increase in inventory reserves and scrap of $5.7 million was the overall increase in inventory balances to support product launches and increased sales volume.

As disclosed on page 68 and page F-7 in the consolidated statement of cash flows, there was a $4.4 million increase in the provision for excess and obsolete inventories for the year ended December 31, 2011 as compared to the year ended December 31,

2010.
Rest of the answer

The remaining increase in inventory reserves of $1.3 million was due to inventory scrap.

Read in the reply
Liquidity and Capital Resources, page 67
SEC asked (17)
We note your disclosure that one of your principal liquidity requirements is capital expenditure needs. Please describe in more detail your commitments for capital expenditures as of your last fiscal period and future expected commitments, if known.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 71 to more specifically identify its expected capital expenditure needs, principally for surgical sets. Though the Company has not entered into any material commitments for these expenditures, it does expect to continue to make investments in surgical sets as it launches new product lines, increases the size of its U.S. sales force, and expands into international markets.
Read in the reply
Liquidity and Capital Resources, page 67
SEC asked (18)
Please identify any known trends or uncertainties that are reasonably likely to materially increase or decrease your liquidity. We note, for example, the changes in coverage policies mentioned on page 13, physician-owned distributorships highlighted on page 17, and regulatory reforms referenced on page 33.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 71 to reflect that its liquidity may be negatively impacted as a result of a decline in sales of its products, including declines due to changes in its customers’ ability to obtain third-party coverage and reimbursement for procedures that use the Company’s products, increased pricing pressure resulting from intensifying competition, and cost increases and slower product development cycles resulting from a changing regulatory environment.
Read in the reply
Off-Balance Sheet Arrangements, page 69
SEC asked (19)
Please tell us how you determined that your arrangement with the entity discussed in note (1) on page 9 is not an off-balance sheet arrangement as that term is used in Regulation S-K Item 303(a)(4).
GMED answered
The Company advises the Staff that it has determined that the arrangement with the entity discussed in note (1) on page 10 is not an off-balance sheet arrangement for the following reasons:

There are no guarantee contracts between the Company and the entity, and as such, the Company has no obligation to the entity under any guarantee contract.

The Company has transferred no assets to the entity and has no retained or contingent interests in assets of the entity or any similar arrangements that serve as credit, liquidity or market risk support to the entity for such assets as of December 31,
Rest of the answer

2011. The Company has one agreement with the entity, and such agreement is a supplier quality agreement that provides no guaranteed commitments or financing to the entity. The terms and provisions of the supply agreement are commensurate with the Company’s supplier quality agreements with other suppliers.

The Company has no obligations under contracts with the entity that would be accounted for as derivative instruments. The only agreement with the entity is the previously-discussed supplier quality agreement.

There are no obligations arising out of a variable interest where the entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with the Company.

Read in the reply
Critical Accounting Policies and Estimates · Significant Factors Used in Determining the Fair Value of Our Common Stock, page 72
SEC asked (20)
Please disclose the significant factors that contributed to the decline in the fair value of your common stock in February and July of 2011 and February of 2012. The disclosure should address the significant factors considered by your company in determining the fair value of your common stock at the various grant dates.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 78 through 80 to disclose the significant factors that contributed to the decline in the fair value of its common stock in February and July of 2011 and February of 2012 as well as the significant factors considered by the Company in determining the fair value of its common stock at the grant dates.
Read in the reply
Critical Accounting Policies and Estimates · Significant Factors Used in Determining the Fair Value of Our Common Stock, page 72
SEC asked (21)
Further, please tell us how your valuations considered the likelihood of achieving a liquidity event, such as an initial public offering or a sale of your company.
GMED answered
The Company respectfully advises the Staff that the valuations considered the likelihood of achieving a liquidity event in the term or time to expiration used in the option-pricing model that was used in each valuation to allocate the total equity value between preferred and common stock. Additionally, the valuations utilized a lack of marketability discount. A summary of the assumed date of a liquidity event and the lack of marketability discounts used in the respective valuations is below.
Read in the reply
Critical Accounting Policies and Estimates · Significant Factors Used in Determining the Fair Value of Our Common Stock, page 72
SEC asked (22)
Please update your disclosure, when you have an estimated initial public offering price range, to discuss each of the significant factors that contribute to the difference, if any, between the fair value of your common stock as of March 28, 2012 and the expected midpoint of the price range of your offering.
GMED answered
The Company acknowledges the Staff’s comment and confirms that once an initial public offering price range has been determined, it will update the disclosure to discuss each of the significant factors that contributed to the difference, if any, between the fair value of the Company’s common stock as of

April 26, 2012 and the expected midpoint of the price range of the Company’s initial public offering.
Read in the reply
Critical Accounting Policies and Estimates · Significant Factors Used in Determining the Fair Value of Our Common Stock, page 72
SEC asked (23)
Please note that we are deferring any final evaluation of stock compensation recognized until the estimated offering price is specified, and we may have further comments in that regard when you file the amendment containing that information.
GMED answered
The Company acknowledges that the Staff may have further comments related to stock compensation recognized after its review of the estimated offering price range included in future filings.
Read in the reply
Overview, page 76
SEC asked (24)
We note the disclosure on page 76 regarding your Adjusted EBITDA since 2004. We further note that the reconciliations on page 10 only include 2009, 2010 and 2011. Please provide all of the disclosures required by Item 10(e) of Regulation S-K.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 82 to eliminate references to Adjusted EBITDA in 2004.

Furthermore, the Company has eliminated any references to Adjusted EBITDA for periods for which reconciliations are not provided.
Read in the reply
Products, page 83
SEC asked (25)
Please provide us with your basis for determining that certain of your products are “firstin-class” as disclosed on page 83.
GMED answered
The Company acknowledges the

Staff’s comment and, in response thereto, has deleted the reference “first-in-class” from its disclosure in Amendment No. 1.
Read in the reply
Intellectual Property, page 92
SEC asked (26)
Please disclose the duration of your patents.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 97 and 98 to disclose the duration of the Company’s patents, by including the following sentence in the first paragraph:

“One of our issued patents expires in March 2015 and the rest of our issued patents expire between November 2019 and June 2030.”
Read in the reply
Intellectual Property, page 92
SEC asked (27)
We note your disclosure that you rely upon licensing opportunities. Please file any material licensing agreements as exhibits, and disclose the material terms of these arrangements.
GMED answered
The Company advises the Staff that it does not rely on any material licensing opportunities, and, as such, there are no material licensing agreements that require filing or other disclosure. In response to the Staff’s comment, the Company has revised the disclosure on page 98 to clarify that it may, in the future, rely upon licensing opportunities.
Read in the reply
Legal Proceedings, page 100
SEC asked (28)
Please tell us whether you believe that the pending merger involving Synthes could impact the direction or outcome of the disclosed litigation.
GMED answered
The Company has no reason to believe that the pending merger involving Synthes will impact the direction or outcome of the disclosed litigation.
Read in the reply
Executive Officers, Significant Employees and Directors, page 102
SEC asked (29)
For each of your directors, please briefly discuss the specific experience, qualifications, attributes or skills that led to the conclusion that the person should serve as a director in light of your business and structure. Refer to Regulation S-K Item 401(e)(1).
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 108 to 111 to discuss, for each of the

Company’s directors, the specific experience, qualifications, attributes or skills that led to the conclusion that the person should serve as a director.
Read in the reply
Director Compensation, page 108
SEC asked (30)
Please provide the director compensation table and disclosure required by Regulation S- K Item 402.
GMED answered
In response to the

Staff’s comment, the Company has revised the disclosure under “Director Compensation” on pages 114 and 115 to include the director compensation table and other disclosure required by Regulation S-K Item 402.
Read in the reply
Certain Relationships, page 129
SEC asked (31)
Please revise to disclose the individual transactions with each related party, including the amount of Series E Preferred stock purchased by each investor.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 124 to specifically identify the individual transactions with each related party. The Company respectfully advises the Staff that all Series E investors were institutional investors and, of the Series E investors, Clarus and the funds affiliated with Goldman, Sachs & Co. are the only related parties.
Read in the reply
Certain Relationships, page 129
SEC asked (32)
We note your reference in this section to financing with institutional investors “including” Clarus and Goldman, and agreements with “certain” of your stockholders. Please revise this section to identify each of the related parties with whom you have agreements. Also, identify the third-party supplier discussed on page 130. Refer to Regulation S-K Item 404(a)(1). File your agreements with this supplier as exhibits.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 125 and 126 to more specifically identify the related parties who are party to the agreements disclosed.

The Company respectfully advises the Staff that the identity of the third-party supplier discussed on page 126 is not material to investors and that naming the supplier in the prospectus would cause substantial competitive harm to the supplier.
Rest of the answer

The Company has disclosed the identity of the Company’s related parties, namely the spouses of two of the

Company’s directors as well as one of the Company’s directors, that have an interest in the third-party supplier and the nature of their relationship with and interest in the third-party supplier. Further, the Company has also disclosed the dollar value of the transactions. Providing the name of the third-party supplier, in addition to the names of the Company’s related parties having an interest in the third-party supplier, would not provide meaningful information to investors about the Company. In contrast, disclosing the name of the third-party supplier will likely substantially injure the third-party supplier.

The third-party supplier sells products to the Company, as well as to other customers, and is seeking to grow its business and sell more of its products and derive more of its revenue from a variety of customers, including the Company’s competitors. The Company understands that the third-party supplier has invested in improving and growing its sales function to achieve such sales goals. It is expected, however, that, if the Company’s competitors were aware of the Company’s relationship with the third-party supplier, they would refuse to purchase products from the third-party supplier. Disclosure of the relationship would therefore be expected to substantially negatively impact the third-party supplier’s sales results and growth prospects and cause the third-party supplier substantial competitive harm. It is important to the Company that its decision to pursue its initial public offering not negatively affect other parties with which it transacts business.

As noted elsewhere in this response letter, the Company’s supplier quality agreement with the third-party supplier is not a material contract required to be filed by Item 601 of Regulation S-K. The Company and the supplier are party to a supplier quality agreement, the terms of which are consistent with those supplier quality agreements the Company has with other suppliers. The supplier quality agreement sets forth terms, such as quality and delivery requirements, by which the Company would purchase products from the third-party supplier if the third-party supplier were to accept a purchase order from the Company, but it does not establish pricing and it does not obligate the Company to purchase a particular quantity of products from the third-party supplier and does not obligate the third-party supplier to supply a particular quantity of products to the Company.

Principal and Selling Stockholders,

Read in the reply
Principal and Selling Stockholders, page 138
SEC asked (33)
Please identify the natural person or persons who have voting or investment control over the shares attributed to Clarus, and the shares attributed to the selling stockholders when you have identified the selling stockholders.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 135 to identify the natural persons who have voting or investment control over the shares attributed to Clarus. The

Company acknowledges the Staff’s comment with respect to the selling stockholders and confirms that when it has identified the selling stockholders, it will update the disclosure to identify the natural persons who have voting or investment control over the shares attributed to the selling stockholders.
Read in the reply
Underwriting, page 146
SEC asked (34)
Revise to state separately the offering expenses that will be borne by the company and the selling stockholders.
GMED answered
In response to the

Staff’s comment, the Company has revised the disclosure on page 143 and page II-1 to state separately the offering expenses that will be borne by the Company and the selling stockholders.
Read in the reply
Financial Statements, page F-1
SEC asked (35)
Please consider on an ongoing basis the updating requirements of Rule 3-12 of Regulation S-X. Note 11. Equity (a) Common Stock, page F-20
GMED answered
Staff’s comment and advises that it has provided updated financial statements and information in the Registration Statement in accordance with the requirements of Rule 3-12 of Regulation S-X to reflect the Company’s first quarter financial results of 2012.

Note 11. Equity

(a) Common Stock, page F-20
Read in the reply
Financial Statements, page F-1
SEC asked (36)
Please disclose the method and significant assumptions used to value the put right. Refer to ASC 825-10-50-10. (b) Series E Preferred Stock, page F-21
GMED answered
In response to the

Staff’s comment, the Company has revised the disclosure on page F-20 to disclose the method and significant assumptions used to value the put right.

(b) Series E Preferred Stock, page F-21
Read in the reply
Financial Statements, page F-1
SEC asked (37)
We note the disclosure on page 54 regarding possible changes in the conversion rate of the Series E preferred stock. Please explain, in summary form, the pertinent rights and privileges of your Series E preferred stock as required by ASC 505-10-50-3. Include a summary of the changes to the conversion rate.
GMED answered
In response to the Staff’s comment, the Company has included revised disclosure in the second paragraph under “(b) Series E Preferred Stock” on pages F-21 and F-22 to disclose a summary of the potential conversion rate adjustments. The Company respectfully advises that all other pertinent rights and privileges of the Series E preferred stock are disclosed as required by ASC 505-10-50-3.
Read in the reply
Exhibit 23.1 Consent of Independent Registered Public Accounting Firm
SEC asked (38)
To the extent there is a delay in requesting effectiveness of your registration statement, an other than typographical change made to the financial statements, or there have been intervening events since the prior filing that are material to the company, please provide a currently dated and signed consent from your independent accountants with your amendments.
GMED answered
The Company has provided a currently dated and signed consent from KPMG LLP, the Company’s independent registered public accounting firm, with Amendment No. 1. The Company acknowledges the Staff’s comment with respect to applicable future amendments to the

Registration Statement.
Read in the reply
Item 15. Recent Sales of Unregistered Securities, page II-3
SEC asked (39)
Please revise to disclose the dates of sale and the amounts of securities sold and the purchasers of the securities. Refer to Regulation S-K Item 701(a) and (b).
GMED answered
In response to the Staff’s comment, the Company advises that all of the Company’s sales of securities during the past three years that were not registered under the Securities Act were grants of stock options or issuances of common stock upon exercises of stock options. The Company has revised the disclosure on pages II-2 and II-3 to identify such grants and issuances in relation to each relevant equity plan.

***********************************

If you require any additional information on these issues, or if we can provide you with any other information that will facilitate your continued
Rest of the answer

review of this filing, please advise us at your earliest convenience. You may reach me at (215) 988-2880.

Read in the reply
Prospectus Summary, page 1
SEC asked (1)
We note your response to prior comment 2. Your summary should present a balanced view of your business. Given your emphasis on your “product development engine” throughout your summary, it is unclear how you determined that the extent of your reliance on three specific products should not be highlighted in your summary.
Rest of the question

Please revise your disclosure, or provide us with additional analysis explaining why such disclosure is not necessary.

GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 2 to disclose the extent of its reliance on three specific products.
Read in the reply
Our Competitive Strengths, page 3
SEC asked (2)
To the extent it is appropriate to highlight your claims regarding your “unique and highly efficient” product development process in your summary, please revise your disclosure in each case to clarify that these claims are based on your beliefs, rather than on independent, objective support, as indicated in your response to prior comment 4.
Rest of the question

In this regard, we note the italicized portions of the third bullet-point under this caption and the first full bullet-point on page 4.

GMED answered
In response to the Staff’s comment, the Company has revised the referenced disclosure on pages 3 and 4, as well as disclosure on pages 87 and 88, to delete the phrase “unique and highly efficient.”
Read in the reply
Implications of Being an Emerging Growth Company, page 5
SEC asked (3)
We note your revisions in response to prior comment 1. Please revise the disclosure in the last bullet point on page 5 to be consistent with your disclosure on page 47 that indicates you have made an election.
GMED answered
In response to the Staff’s comment, the Company has revised the disclosure on page 6 to indicate that the Company has elected to use an extended transition period for complying with new or revised accounting standards.
Read in the reply
Supplier, page 126
SEC asked (4)
Please expand your response to prior comment 32 to explain how you determined that your agreement with the supplier discussed here is not required to be filed by Regulation S-K Item 601(b)(10)(ii)(A), or file the agreement as an exhibit.
GMED answered
As the Company advised the Staff in its May 8, 2012 response to the Staff’s prior comment 32, the Company believes that the supplier quality agreement with the supplier referred to on page 127 is not material to investors and is not a “material contract” required to be filed by Item 601 of Regulation S-K.

The Company respectfully advises the Staff that the parties to the referenced supplier quality agreement are the Company and the third-party supplier.
Rest of the answer

No director, officer, promoter, voting trustee, security holder named in the Registration Statement, or underwriter is a party to the supplier quality agreement, and as such, Regulation S-K Item 601(b)(10)(ii)(A) does not require that the agreement be filed as an exhibit.

Further, as noted in the Company’s response to the Staff’s prior comment 32, the supplier quality agreement does not include any commercial terms or create any material rights or obligations of either party. In fact, the agreement, which is consistent with those supplier agreements the Company has with its other suppliers, simply sets forth a framework, including quality and delivery requirements, for possible purchases by the Company. The supplier quality agreement does not establish pricing or other material terms, and it does not obligate the Company to purchase a particular quantity of products from the third-party supplier or obligate the third-party supplier to supply a particular quantity of products to the Company. Purchases by the Company are made from time to time by the Company pursuant to purchase orders, when the third-party supplier accepts the purchase order from the Company. These arrangements are done in the ordinary course of business and are entirely consistent with arrangements that the Company has with its other suppliers.

Regulation S-K Item 601(b)(10)(ii)(B) provides that a “contract upon which the registrant’s business is substantially dependent, as in the case of continuing contracts to … purchase the major part of the registrant’s requirements of goods, services or raw materials” is a “material contract.” Although the Company has purchased products from the third-party supplier under purchase orders, the Company’s business is not substantially dependent on the supplier quality agreement, as there are no purchase or supply requirements at all in the contract.

As disclosed in the Registration Statement, the Company’s products are manufactured through a network of over 100 third-party suppliers. The Company has readily available to it alternative sources of supply for each of its products and further believes it carries sufficient inventory on hand to avoid any disruptions or delays in sales should any third-party supplier cease supplying the Company with a product, including the supplier in question. Furthermore, for the products that the Company purchases from this particular supplier for use in its most significant products, the REVERE 5.5 Titanium Degen System,

COALITION and CALIBER, it also currently purchases those products from a secondary source to ensure a constant supply. As a result of this multi-sourcing, combined with its available inventory on hand, the Company believes that it could transition its supplier arrangements and start using new additional suppliers without disruptions or delays in sales if this third-party supplier ceased supplying the Company with these products. Accordingly, the Company believes that ceasing to do business with this particular third-party supplier would not materially adversely affect its business.

Accordingly, the Company believes that the supplier quality agreement with the third-party supplier does not constitute a “material contract” within the definition of Regulation S-K and is not required to be filed as an exhibit.

Read in the reply
Financial Statements, page F-1
SEC asked (5)
We note that you plan to effect a reverse stock split of your outstanding common stock immediately prior to the closing of the offering. Please tell us how you considered SAB Topic 4.C.
GMED answered
In response to the Staff’s comment, the Company confirms that, when the ratio for the reverse stock split is determined, the Company will revise the Registration Statement to give it retroactive effect in the balance sheet. The Company also confirms that an appropriately cross-referenced note will disclose the retroactive treatment, explain the change made and state the date the change became effective.

The Company will supply supplemental information to the Staff concerning the reverse stock split and proposed price range for the offering as soon as those items are determined.
Read in the reply
Note 13. Variable Interest Entities, page F-28
SEC asked (6)
Please tell us about your analysis underlying your initial determination to consolidate the VIE in 2009 and your subsequent analysis to de-consolidate the VIE after 2009.
GMED answered
The Company respectfully advises the Staff that the initial determination to consolidate the supplier referred to on page F-28 was made in 2005. The supplier was initially capitalized with a $2.0 million loan from the Company in 2005. The loan represented a financial interest in the supplier which exposed the Company to the risks and rewards of the VIE.
Rest of the answer

At that point in time, significant capital had not been contributed by the initial shareholders of the supplier and the total equity investment in the supplier prior to the loan was insufficient to permit the supplier to finance its activities without the financial support of other parties. As a result, the supplier was a VIE and the Company was its primary beneficiary, because the Company was the only entity that provided financing to the VIE and had capital at risk and thus, would absorb the majority of the losses of the VIE. Accordingly, the VIE was consolidated under the predecessor to the current guidance under ASC 810, originally promulgated in FIN 46(R).

In February 2008, the supplier repaid the $2.0 million loan to the Company. The supplier’s repayment of the loan made by the Company eliminated any explicit variable interest in the entity as the Company no longer held a direct financial interest in the VIE and the Company’s supply contracts with the VIE were short term arrangements at market prices that did not obligate a specific volume of purchases. However, after the repayment of the loan the Company believed that it still held an implicit variable interest in the VIE due to the Company’s CEO holding ownership and significant voting control of both the Company and the VIE and due to there being no significant outside investor capital at risk in the supplier. The Company could not demonstrate at the time that it would not protect its CEO and controlling stockholder from declines in the value of his ownership interest in the supplier. Accordingly, the Company continued to consolidate the VIE in 2008. This is consistent with guidance originally promulgated in

FSP FIN 46R-5.

In December 2009, an outside investor purchased $2.0 million of the supplier’s common stock. This stock represented the most subordinated class of equity in the supplier, absorbing first losses. The outside investor was not an officer, director or employee of the Company and therefore, had no direct or indirect involvement with the Company’s governance. Additionally, the outside investor was not a related party of the Company, the CEO or the Company’s management group. The investment by the outside investor provided outside capital at risk, which further distinguished the operations of the Company and the supplier, and by this point, the supplier was operating profitably as a distinct and separate entity from the Company. Further, the outside investment reduced the CEO’s voting interest in the supplier to a minority stake.

The Company concluded that the implicit variable interest was eliminated upon the contribution of significant risk capital by the outside investor in December 2009. As a result of the outside investment, there was significant subordinated capital in the entity that absorbs losses first. Further, ongoing sales of equity by both entities had diluted the

CEO’s interest to a noncontrolling interest in the supplier, and transactions between the Company and the supplier were also subject to oversight by governance provisions to prevent self-dealing. These governance provisions are described further below. The Company also notes that in 2009 the supplier ceased occupying shared space and services with the Company, establishing an independent geographical location. The only relationship between the Company and supplier as of the deconsolidation date is in a vendor/customer capacity whereby the Company purchases components on a purchase order by purchase order basis.

As a result of the factors described, the Company believes any implicit variable interest in the VIE was eliminated with the infusion of outside capital in December 2009. While the determination of when an implicit variable interest is extinguished necessarily requires judgment, the Company believes it would be inappropriate to continue to consolidate an entity that is independently funded and outside the implicit or explicit control of the Company. From a technical accounting standpoint, without a non-equity variable interest to implicitly protect the equity holders, the entity qualifies as a voting interest entity and the Company has no economic interest in the entity. Therefore the entity was deconsolidated in December 2009. There have been no changes since December 2009 that would indicate that the Company has a variable interest in the supplier, that the Company has power or control over the supplier, or that the entity should be considered a VIE.

As it relates to governance and oversight, the Company’s Investor Rights Agreement, dated July 23, 2007 and amended on January 14, 2009, requires prior approval of the majority of the board of directors for any action that results in the consummation of any transaction with any of the Company’s officers, directors, stockholders, employees or affiliates, or any family member or any affiliate of the foregoing. Additionally, the Company follows purchasing policies and procedures for all vendors that require a close bid process (generally a minimum of five vendors) for the procurement of all inventories. Once quotes are received from all vendors, the purchasing department analyzes all of the vendors and quotes for the quality of the products previously ordered from the vendor, impact on projects the vendor is currently servicing for the Company, trends in the on-time delivery of products, and pricing. The Company has no long-term supply agreements or commitments with the supplier in question and the Company can cease using the VIE for a specific project, or altogether, with no penalties. The Company’s CEO and management group do not participate in purchasing decisions, and the Company believes these controls ensure all transactions with the supplier are made on an arm’s-length basis.

While the Company does not have a variable interest in the supplier or control its decision-making, because of the shareholdings in the supplier by the Company’s CEO and others, it believes it is important to disclose transactions between the two entities in a clear and transparent manner. Those disclosures are included in note 16 to the Company’s consolidated financial statements and the section of the Registration Statement labeled

“Certain Relationships and Related-Party Transactions.”

***********************************

If you require any additional information on these issues, or if we can provide you with any other information that will facilitate your continued review of this filing, please advise us at your earliest convenience. You may reach me at (215) 988-2880, or in the alternative, Beth Diffley, at (215) 988-2607.

Read in the reply

Also in this review: company letter, Jun 11, 2012, company letter, Jul 3, 2012

Letters without questions

Other letters

UPLOAD and CORRESP
6 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 21 letters filed since 2012-04-25. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.